Accordingly, RND3 expression and suppressed RHOA signaling appear to be important for normal melanoma cell movement, whereas RND3 downregulation and enhanced RHOA signaling are critical in BRAF-inhibitor treated cells. The gene discussed is RND3; the disease is melanoma.